Novo Nordisk slams Danish Medicines Council's methodology: Has flaws and shortcomings

Novo Nordisk’s Danish management has sent a strongly worded letter criticizing the Danish Medicines Council’s use of meta-analysis following the release of Denmark’s first treatment guideline for type 2 diabetes.

Kasper Bødker Mejlvang, general manager for Denmark and Iceland at Novo Nordisk | Photo: Novo Nordisk / PR

A few weeks ago, Novo Nordisk expressed its discontent in a letter sent to the Danish Medicines Council over its treatment guidelines for type 2 diabetes.

According to the treatment guide, cheaper sulfonylureas medications were on the same level as GLP 1 analogs, supplementing the first-line diabetes treatment, metformin, for patients without comorbidities or other increased risk factors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs